<SEC-DOCUMENT>0001213900-24-081980.txt : 20240926
<SEC-HEADER>0001213900-24-081980.hdr.sgml : 20240926
<ACCEPTANCE-DATETIME>20240926083202
ACCESSION NUMBER:		0001213900-24-081980
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240926
FILED AS OF DATE:		20240926
DATE AS OF CHANGE:		20240926

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		241326240

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0215700-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED
STATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
AND EXCHANGE COMMISSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
6-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 13a-16 or 15d-16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of: September 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-36578</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ENLIVEX
THERAPEUTICS LTD.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>14
Einstein Street, Nes Ziona, Israel 7403618</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2024, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (&ldquo;Enlivex&rdquo;),
issued a press release announcing that the Danish Medicines Agency authorized the initiation of the Phase II stage of
Enlivex&rsquo;s multi-country Phase I/II trial in moderate and severe knee osteoarthritis. A copy of such press release is furnished
as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea021570001ex99-1_enlivex.htm">Press Release issued by Enlivex Therapeutics Ltd. on September 26, 2024.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex
    Therapeutics Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oren Hershkovitz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz<BR>
    Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
September 26, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021570001ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON SEPTEMBER 26, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Enlivex
Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients
with Moderate to Severe Knee Osteoarthritis</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nes-Ziona,
Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage macrophage
reprogramming immunotherapy company, today announced that the Danish Medicines Agency authorized the initiation of the Phase II stage
of the Company&rsquo;s multi-country Phase I/II trial in moderate and severe knee osteoarthritis. This approval follows the recently
announced recommendation by the independent Data and Safety Monitoring Board (DSMB) that the Company may move forward to the Phase II
stage of the trial.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase I/II multi-center clinical trial is composed of two stages. The first stage is a Phase I safety run-in, open-label dose escalation
phase to characterize the safety and tolerability of Allocetra&trade; injections to the target knee in order to identify the dose and
injection regimen for the subsequent Phase II stage. The Phase II stage is a double-blind, randomized, placebo-controlled stage, which
the Company is now initiating following the completion of the safety run-in stage and the safety confirmation by the DSMB, which the
Company recently announced. In addition to evaluating safety, the blinded randomized stage is statistically-powered to assess the efficacy
of Allocetra&trade; injections into the knee. The Company expects that the primary measurements will evaluate joint-pain and joint-function
in comparison to placebo at three months, six months and 12 months after treatment.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Einat
Galamidi, MD, Medical Vice President of Enlivex, commented, &ldquo;We are pleased with the safety profile of Allocetra&trade; following
three sequential intra-articular knee injections, as demonstrated in the first twelve patients in the Phase I safety run-in stage of
this trial, and the approval to progress into the double-blind, randomized, placebo controlled Phase II stage.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
KNEE OSTEOARTHRITIS<SUP>1</SUP></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Osteoarthritis
is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide.
About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis
by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing
knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States,
primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant
disability for persons with osteoarthritis is critical. There are currently no medications approved by either the U.S. Food and Drug
Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural
damage in the joint.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
The Arthritis Foundation; Disease modification in osteoarthritis; pathways to drug approval, Katz et. Al., Osteoarthritis and Cartilage
Open (2) (2020)</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
ENLIVEX</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex
is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra&trade;, a universal, off-the-shelf cell therapy
designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is
critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit&nbsp;https://enlivex.com/.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Safe
Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo;
&ldquo;has the potential to&rdquo; and other words of similar meaning, including statements regarding expected cash balances, market
opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities
for, ALLOCETRA<SUP>TM</SUP> programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that
may affect Enlivex&rsquo;s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing
any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may
not generate data that would support the approval or marketing of these products for the indications being studied or for other indications;
that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to
differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results
that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly
from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<SUP>TM</SUP> product line
could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements
for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing
and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described
above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex&rsquo;s
filings with the Securities and Exchange Commission, including in the Company&rsquo;s most recent Annual Report on Form 20-F filed with
the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the
statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable
law.</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENLIVEX
CONTACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shachar
Shlosberger, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex
Therapeutics, Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shachar@enlivexpharm.com</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR
RELATIONS CONTACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave
Gentry, CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RedChip
Companies Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-407-644-4256</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENLV@redchip.com</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  J )8# 2(  A$! Q$!_\0
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MQTS_ (*&_!JZO]5U.[&G:?:V)\.^/E</JC[8XBXV 1LX5APY4#-?HE#^T%\
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MMKSQ7X\D?1SXRAUS1))FBT#PGH"ZQXKF\1PRO%!]EMF+#S5!^'?B/^SOH?\
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MXOF4FN=<UU>=EMHM4?J1-XD\*V=K<7U]XJ\-V^GVN?MEW>>(]&_LSMU^G?\
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'+;:_S9__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
